227 related articles for article (PubMed ID: 16480284)
1. Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors.
Klutchko SR; Zhou H; Winters RT; Tran TP; Bridges AJ; Althaus IW; Amato DM; Elliott WL; Ellis PA; Meade MA; Roberts BJ; Fry DW; Gonzales AJ; Harvey PJ; Nelson JM; Sherwood V; Han HK; Pace G; Smaill JB; Denny WA; Showalter HD
J Med Chem; 2006 Feb; 49(4):1475-85. PubMed ID: 16480284
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.
Smaill JB; Palmer BD; Rewcastle GW; Denny WA; McNamara DJ; Dobrusin EM; Bridges AJ; Zhou H; Showalter HD; Winters RT; Leopold WR; Fry DW; Nelson JM; Slintak V; Elliot WL; Roberts BJ; Vincent PW; Patmore SJ
J Med Chem; 1999 May; 42(10):1803-15. PubMed ID: 10346932
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
[TBL] [Abstract][Full Text] [Related]
4. Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors.
Emanuel SL; Hughes TV; Adams M; Rugg CA; Fuentes-Pesquera A; Connolly PJ; Pandey N; Moreno-Mazza S; Butler J; Borowski V; Middleton SA; Gruninger RH; Story JR; Napier C; Hollister B; Greenberger LM
Mol Pharmacol; 2008 Feb; 73(2):338-48. PubMed ID: 17975007
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions.
Smaill JB; Rewcastle GW; Loo JA; Greis KD; Chan OH; Reyner EL; Lipka E; Showalter HD; Vincent PW; Elliott WL; Denny WA
J Med Chem; 2000 Apr; 43(7):1380-97. PubMed ID: 10753475
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family.
Smaill JB; Gonzales AJ; Spicer JA; Lee H; Reed JE; Sexton K; Althaus IW; Zhu T; Black SL; Blaser A; Denny WA; Ellis PA; Fakhoury S; Harvey PJ; Hook K; McCarthy FO; Palmer BD; Rivault F; Schlosser K; Ellis T; Thompson AM; Trachet E; Winters RT; Tecle H; Bridges A
J Med Chem; 2016 Sep; 59(17):8103-24. PubMed ID: 27491023
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
Thompson AM; Murray DK; Elliott WL; Fry DW; Nelson JA; Showalter HD; Roberts BJ; Vincent PW; Denny WA
J Med Chem; 1997 Nov; 40(24):3915-25. PubMed ID: 9397172
[TBL] [Abstract][Full Text] [Related]
8. Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor.
Smaill JB; Showalter HD; Zhou H; Bridges AJ; McNamara DJ; Fry DW; Nelson JM; Sherwood V; Vincent PW; Roberts BJ; Elliott WL; Denny WA
J Med Chem; 2001 Feb; 44(3):429-40. PubMed ID: 11462982
[TBL] [Abstract][Full Text] [Related]
9. Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
Ballard P; Barlaam BC; Bradbury RH; Dishington A; Hennequin LF; Hickinson DM; Hollingsworth IM; Kettle JG; Klinowska T; Ogilvie DJ; Pearson SE; Scott JS; Suleman A; Whittaker R; Williams EJ; Wood R; Wright L
Bioorg Med Chem Lett; 2007 Nov; 17(22):6326-9. PubMed ID: 17869514
[TBL] [Abstract][Full Text] [Related]
10. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
11. The discovery of highly selective erbB2 (Her2) inhibitors for the treatment of cancer.
Lippa B; Kauffman GS; Arcari J; Kwan T; Chen J; Hungerford W; Bhattacharya S; Zhao X; Williams C; Xiao J; Pustilnik L; Su C; Moyer JD; Ma L; Campbell M; Steyn S
Bioorg Med Chem Lett; 2007 Jun; 17(11):3081-6. PubMed ID: 17398092
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a novel Her-1/Her-2 dual tyrosine kinase inhibitor for the treatment of Her-1 selective inhibitor-resistant non-small cell lung cancer.
Cha MY; Lee KO; Kim JW; Lee CG; Song JY; Kim YH; Lee GS; Park SB; Kim MS
J Med Chem; 2009 Nov; 52(21):6880-8. PubMed ID: 19888761
[TBL] [Abstract][Full Text] [Related]
13. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.
Rusnak DW; Affleck K; Cockerill SG; Stubberfield C; Harris R; Page M; Smith KJ; Guntrip SB; Carter MC; Shaw RJ; Jowett A; Stables J; Topley P; Wood ER; Brignola PS; Kadwell SH; Reep BR; Mullin RJ; Alligood KJ; Keith BR; Crosby RM; Murray DM; Knight WB; Gilmer TM; Lackey K
Cancer Res; 2001 Oct; 61(19):7196-203. PubMed ID: 11585755
[TBL] [Abstract][Full Text] [Related]
14. Novel inhibitors of epidermal growth factor receptor: (4-(Arylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)(1H-indol-2-yl)methanones and (1H-indol-2-yl)(4-(phenylamino)thieno[2,3-d]pyrimidin-6-yl)methanones.
Beckers T; Sellmer A; Eichhorn E; Pongratz H; Schächtele C; Totzke F; Kelter G; Krumbach R; Fiebig HH; Böhmer FD; Mahboobi S
Bioorg Med Chem; 2012 Jan; 20(1):125-36. PubMed ID: 22169601
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2).
Wissner A; Overbeek E; Reich MF; Floyd MB; Johnson BD; Mamuya N; Rosfjord EC; Discafani C; Davis R; Shi X; Rabindran SK; Gruber BC; Ye F; Hallett WA; Nilakantan R; Shen R; Wang YF; Greenberger LM; Tsou HR
J Med Chem; 2003 Jan; 46(1):49-63. PubMed ID: 12502359
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimido[5,4-d]pyrimidines designed as inhibitors of the epidermal growth factor receptor.
Rewcastle GW; Bridges AJ; Fry DW; Rubin JR; Denny WA
J Med Chem; 1997 Jun; 40(12):1820-6. PubMed ID: 9191958
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor.
Rewcastle GW; Palmer BD; Thompson AM; Bridges AJ; Cody DR; Zhou H; Fry DW; McMichael A; Denny WA
J Med Chem; 1996 Apr; 39(9):1823-35. PubMed ID: 8627606
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src.
Plé PA; Green TP; Hennequin LF; Curwen J; Fennell M; Allen J; Lambert-Van Der Brempt C; Costello G
J Med Chem; 2004 Feb; 47(4):871-87. PubMed ID: 14761189
[TBL] [Abstract][Full Text] [Related]
19. Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines.
Traxler P; Bold G; Frei J; Lang M; Lydon N; Mett H; Buchdunger E; Meyer T; Mueller M; Furet P
J Med Chem; 1997 Oct; 40(22):3601-16. PubMed ID: 9357527
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of EGFR tyrosine kinase inhibition by C-C multiple bonds-containing anilinoquinazolines.
Ban HS; Tanaka Y; Nabeyama W; Hatori M; Nakamura H
Bioorg Med Chem; 2010 Jan; 18(2):870-9. PubMed ID: 19969465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
